Jiangsu Chiatai Qingjiang Pharmaceutical Co., Ltd.

Methods: Chinese healthy subjects were used as test subjects. A self-crossover design was used to determine the time course of plasma concentration of crisaborole in healthy subjects after administration of crisaborole ointment [Specification: 2% (30 g: 0.6 g)] developed by Jiangsu Zhengda Qingjiang Pharmaceutical Co., Ltd., and the corresponding pharmacokinetic parameters were estimated. Clisborole ointment [trade name: Staquis®, specification: 2%] licensed by Anacor Pharmaceuticals, Inc. and produced by Pharmacia and Upjohn Company LLC was used as the reference preparation to evaluate the bioequivalence between the preparations and observe the safety of crisaborole ointment in Chinese healthy subjects.

Primary objective: To evaluate the pharmacokinetic interaction between QJ-19-0002 and colchicine. Secondary objectives: 1. To evaluate the safety and tolerability of QJ-19-0002 combined with colchicine in healthy subjects. 2. To investigate the pharmacodynamic (PD) characteristics of QJ-19-0002 combined with colchicine in healthy subjects.

Primary objective: To evaluate the effectiveness of inhaled bromhexine hydrochloride solution in improving the symptoms of sticky sputum in lower respiratory tract infections; Secondary objective: To evaluate the safety of inhaled bromhexine hydrochloride solution in improving the symptoms of sticky sputum in lower respiratory tract infections.